Gastroenterology: Upadacinib's treatment of moderate-to-severe Crohn's disease phase II clinical success

Recently, researchers evaluated the efficacy and safety of Upadacitinib, an oral selective Janus kinase 1 inhibitor, for Crohn's disease (CD)the study was a double-blind, Phase 2 trial in which patients with moderate to severe CD in adults were given insufficient or intolerable response toimmunodeficiencyinhibitors or tumor necrosis factor antagonists, and were given a placebo at random, taking 3 mg, 6 mg, 12 mg or 24 mg Upadacitinib or Upadacitinib 24 mg twice a day, and a recolonoscopy at 12 or 16 weeksPatients who completed the treatment at the 16th week continued up to 36 weeks of Upadacitinib maintenance therapyThe main endpoints of the study were 16 weeks of clinical remission and 12 weeks or 16 weeks of endoscopic remission220 patients participated in the study, with clinical remission in 3 mg, 6 mg, 12 mg, 24 mg (2 times daily) and 24 mg (1 daily) Upadacitinib, respectively, clinical remission, compared with 11% of the placebo mitigation rateThe above-mentioned endoscopic remission rates were 10%, 8%, 8%, 22% and 14%, respectively, and there was no endoscopic remission in the placebo groupDuring the induction period, with the increase of dose, the endoscopic remission rate increased, but the clinical mitigation rate had no significant effect, and the rate of mitigation in each group was sustainable to the 52nd weekDuring the induction period, patients in the Upadacitinib group had a higher incidence ofand severe infections than in the placebo groupThe totalcholesterol, HDL and LDL cholesterol levels increased significantly in patients in the 12mg and 24mg Upadacitinib group twice dailyclinical studies have shown that Upadacitinib therapy can improve endoscopy rates in patients with moderate to severe Crohn's disease